HIV and malaria interactions: where do we stand?

被引:0
|
作者
Gonzalez, Raquel [1 ]
Ataide, Ricardo [2 ]
Naniche, Denise [1 ]
Menendez, Clara [1 ]
Mayor, Alfredo [1 ]
机构
[1] Univ Barcelona, Hosp Clin IDIBAPS, Barcelona Ctr Int Heath Res CRESIB, E-08007 Barcelona, Spain
[2] Univ Edinburgh, Sch Biol Sci, Inst Immunol & Infect Res, Ctr Immun Infect & Evolut, Edinburgh EH8 9YL, Midlothian, Scotland
关键词
antimalarial; antiretrovirals; drug; epidemiology; HIV; immunity; impact; interaction; malaria; HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMODIUM-FALCIPARUM-MALARIA; TO-CHILD TRANSMISSION; SUB-SAHARAN AFRICA; PLACENTAL MALARIA; PREGNANT-WOMEN; VIRAL LOAD; COTRIMOXAZOLE PROPHYLAXIS; PROTEASE INHIBITORS; CELL COUNT;
D O I
10.1586/ERI.11.167
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Reversing the spread of HIV infection and the incidence of malaria constitute two of the Millenium Development Goals. However, despite recent achievements, both diseases still entail global heath problems. Furthermore, their overlapping geographical distribution raises concerns and challenges for potential immunological, clinical and therapeutic interactions. It has been reported that HIV infection increases malaria susceptibility and reduces the efficacy of antimalarial drugs. On the other hand, the effect of malaria on HIV-infected individuals has also been explored, with the parasitic infection increasing the risk of HIV disease progression and mother-to-child transmission of HIV. The spread of malaria and parasite resistance to antimalarials could also be accelerated by HIV-associated immunosuppresion. Current knowledge of the epidemiological, clinical, immunological and therapeutic interactions of the two diseases is reviewed in this article. We focus on the latest available data, pointing out key future research areas and challenges of the field.
引用
收藏
页码:153 / 165
页数:13
相关论文
共 50 条
  • [1] Malaria therapy: where do we stand, what next?
    Grobusch, Martin Peter
    van Vugt, Michele
    FUTURE MICROBIOLOGY, 2010, 5 (10) : 1447 - 1449
  • [2] Impact of malaria on HIV infection
    Martin-Blondel, G.
    Soumah, M.
    Camara, B.
    Chabrol, A.
    Porte, L.
    Delobel, P.
    Cuzin, L.
    Berry, A.
    Massip, P.
    Marchou, B.
    MEDECINE ET MALADIES INFECTIEUSES, 2010, 40 (05): : 256 - 267
  • [3] The HIV self-testing debate: where do we stand?
    Gagnon, Marilou
    French, Martin
    Hebert, Yamilee
    BMC INTERNATIONAL HEALTH AND HUMAN RIGHTS, 2018, 18
  • [4] Autoantibodies and Malaria: Where We Stand? Insights Into Pathogenesis and Protection
    Mourao, Luiza Carvalho
    Cardoso-Oliveira, Gustavo Pereira
    Braga, Erika Martins
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2020, 10
  • [5] Hepatitis B virus in the Arab world: Where do we stand?
    Gasim, Gasim Ibrahim
    ARAB JOURNAL OF GASTROENTEROLOGY, 2013, 14 (02) : 35 - 43
  • [6] Orphans and vulnerable children affected by HIV/AIDS in Brazil: Where do we stand and where are we heading?
    Franca-Junior, Ivan
    Doring, Marlene
    Stella, Isete Maria
    REVISTA DE SAUDE PUBLICA, 2006, 40 : 23 - 30
  • [7] Cardiovascular health in people with perinatally acquired HIV - where do we stand?
    Majonga, Edith D.
    Henderson, Merle
    Ferrand, Rashida A.
    CURRENT OPINION IN HIV AND AIDS, 2024, 19 (06) : 348 - 354
  • [8] Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?
    Mehellou, Youcef
    De Clercq, Erik
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (02) : 521 - 538
  • [9] Tuberculosis in Mozambique: Where Do We Stand?
    Nguenha D.
    Manhiça I.
    Garcia-Basteiro A.L.
    Cowan J.
    Current Tropical Medicine Reports, 2018, 5 (4) : 264 - 272
  • [10] Rifabutin: where do we stand in 2016?
    Crabol, Yoann
    Catherinot, Emilie
    Veziris, Nicolas
    Jullien, Vincent
    Lortholary, Olivier
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (07) : 1759 - 1771